A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ALT 2074 [SYI 2074] in Subjects With Type 2 Diabetes Who Have a Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ALT 2074 [SYI 2074] in Subjects With Type 2 Diabetes Who Have a Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2008

At a glance

  • Drugs SYI 2074 (Primary)
  • Indications Acute coronary syndromes; Coronary artery disease
  • Focus Pharmacodynamics
  • Sponsors Synvista Therapeutics
  • Most Recent Events

    • 04 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top